HRS-7535
GLP-1 (small molecule) · oral · Hengrui
Summary
- Also known as
- Hengrui
- Mechanism
- GLP-1 (small molecule)
- Route
- oral
- Company
- Hengrui
- Highest development stage
- filed
- Status (as of data cut)
- Phase 3 positive: OUTSTAND-1/-2 (T2D), HARBOR-1 (obesity); NDAs accepted in China for T2D and weight management (Sep 2026) verify
- Next milestone
- China approval
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 3 positive phase 3 | Positive phase 3 HARBOR-1; NDA accepted Sep 2026 | Hengrui NDA announcement (Sep 2026) |
| T2D | 3 positive phase 3 | Positive phase 3 OUTSTAND-1/-2; NDA accepted Sep 2026 | Hengrui NDA announcement (Sep 2026); OUTSTAND-1 (EASD 2026) |
| CV outcomes | 0 no data | ||
| CKD | 2 phase 3 ongoing | Phase 3 registered on ClinicalTrials.gov | |
| HFpEF | 1 phase 2 / signal | Phase 2 only | |
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HRS-7535 phase 2 (add-on to metformin + SGLT2i) | HRS-7535 30 mg | t2d china | 16 | 51 | — | — | −1.5 vs −0.4 | 0.0 vs 2.0 | — | 15.7 vs 2.0 | 13.7 vs 2.0 | 7.8 vs 0.0 | — | verified |
| HRS-7535 phase 2 (add-on to metformin + SGLT2i) | HRS-7535 60 mg | t2d china | 16 | 53 | — | —−2.4 % vs −0.7 % estimand not specified | −1.8 vs −0.4 | 0.0 vs 2.0 | — | 21.2 vs 2.0 | 19.2 vs 2.0 | 3.8 vs 0.0 | — | verified |
| HARBOR-1 (HRS-7535-303, NCT06904105) | 120 mg | obesity china | 44 | 556 | −9.5 % vs −2.5 % Δ −7.0 pp | −8.0 % vs −2.4 % Δ −5.6 pp | — | 4.1 vs 2.7 | — | 70.3 vs 16.2 | 66.7 vs 4.5 | — | — | press release |
| HARBOR-1 (HRS-7535-303, NCT06904105) | 180 mg | obesity china | 44 | 556 | −10.9 % vs −2.5 % Δ −8.4 pp | −9.8 % vs −2.4 % Δ −7.4 pp | — | 3.1 vs 2.7 | — | 70.0 vs 16.2 | 68.6 vs 4.5 | — | — | press release |
| OUTSTAND-1 (HRS-7535-301, NCT06672172) | 30 mg | t2d china | 32 | 284 | — | — | −1.4 vs −0.2 | 1.4 vs 0.0 | — | — | — | — | — | congress |
| OUTSTAND-1 (HRS-7535-301, NCT06672172) | 60 mg | t2d china | 32 | 284 | — | — | −1.4 vs −0.2 | 2.9 vs 0.0 | — | — | — | — | — | congress |
| OUTSTAND-1 (early T2D, monotherapy) | oral HRS-7535 90 mg | t2d china | 32 | 284 | — | — | −1.7 vs −0.1 | 6.9 vs 0.0 | — | — | — | — | — | congress |
| OUTSTAND-2 (HRS-7535-302, NCT06589765) | 30 mg vs dapagliflozin 10 mg: HbA1c -1.28 | t2d china | 32 | 810 | — | — | −1.6 | 4.0 | — | — | — | — | — | press release |
| OUTSTAND-2 (HRS-7535-302, NCT06589765) | 60 mg vs dapagliflozin 10 mg: HbA1c -1.28 | t2d china | 32 | 810 | — | — | −1.5 | 3.9 | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- oral HRS-7535 90 mg: Efficacy estimand; treatment-policy −1.63 % vs −0.18 %
- HRS-7535 30 mg: HbA1c from the abstract (estimand not named; ESM: primary estimand uses a hypothetical strategy). Safety from ESM Tables 5–6. Weight for 30 mg not reported; main text not available to us.
- HRS-7535 60 mg: HbA1c from the abstract (estimand not named; ESM: primary estimand uses a hypothetical strategy). Safety from ESM Tables 5–6. Weight for 30 mg not reported; main text not available to us.
Verbatim quotes from the source (31)
- oral HRS-7535 90 mg · hba1c · abstract
reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
- oral HRS-7535 90 mg · ae_dc · abstract
mg), and 6.9% (90 mg) versus 0% with pbo in the 32-week period.
- 30 mg · hba1c · abstract
reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
- 30 mg · ae_dc · abstract
Discontinuation due to AEs occurred in 1.4% (30 mg), 2.9% (60
- 60 mg · hba1c · abstract
reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
- 60 mg · ae_dc · abstract
Discontinuation due to AEs occurred in 1.4% (30 mg), 2.9% (60
- 30 mg · hba1c · press release
Based on the efficacy estimand^3, the reductions in HbA1c from baseline for the HRS-7535 30 mg, 60 mg, and 90 mg groups and the dapagliflozin 10 mg group were 1.58%, 1.50%, 1.68%, and 1.28%, respectively.
- 30 mg · ae_dc · abstract
Adverse events leading to discontinuation occurred in 4.0%, 3.9% and 3.9% versus 1.0%
- 60 mg · hba1c · press release
Based on the efficacy estimand^3, the reductions in HbA1c from baseline for the HRS-7535 30 mg, 60 mg, and 90 mg groups and the dapagliflozin 10 mg group were 1.58%, 1.50%, 1.68%, and 1.28%, respectively.
- 60 mg · ae_dc · abstract
Adverse events leading to discontinuation occurred in 4.0%, 3.9% and 3.9% versus 1.0%
- 120 mg · weight_tp · press release
Based on the treatment policy estimand^2, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 8.0% and 9.8% from baseline at Week 44, respectively, compared to 2.4% with placebo.
- 120 mg · nausea · press release
nausea (70.3% and 70.0% vs. 16.2% with placebo)
- 120 mg · vomiting · press release
vomiting (66.7% and 68.6% vs. 4.5% with placebo)
- 120 mg · ae_dc · press release
Treatment discontinuation rates due to TEAEs were 4.1% (120 mg) and 3.1% (180 mg) for HRS-7535 vs. 2.7% with placebo.
- 120 mg · weight_eff · press release
Based on the efficacy estimand^1, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 9.5% and 10.9% from baseline at Week 44, respectively, compared to 2.5% with placebo.
- 180 mg · weight_tp · press release
Based on the treatment policy estimand^2, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 8.0% and 9.8% from baseline at Week 44, respectively, compared to 2.4% with placebo.
- 180 mg · nausea · press release
nausea (70.3% and 70.0% vs. 16.2% with placebo)
- 180 mg · vomiting · press release
vomiting (66.7% and 68.6% vs. 4.5% with placebo)
- 180 mg · ae_dc · press release
Treatment discontinuation rates due to TEAEs were 4.1% (120 mg) and 3.1% (180 mg) for HRS-7535 vs. 2.7% with placebo.
- 180 mg · weight_eff · press release
Based on the efficacy estimand^1, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 9.5% and 10.9% from baseline at Week 44, respectively, compared to 2.5% with placebo.
- HRS-7535 30 mg · ae_dc · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
TEAEs leading to treatment discontinuation 1 (2.0) 0 0
- HRS-7535 30 mg · nausea · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
Nausea 1 (2.0) 8 (15.7) 11 (21.2)
- HRS-7535 30 mg · vomiting · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
Vomiting 1 (2.0) 7 (13.7) 10 (19.2)
- HRS-7535 30 mg · sae · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
Serious adverse events 0 4 (7.8) 2 (3.8)
- HRS-7535 30 mg · hba1c · Abstract RESULTS
placebo (n=51). At week 16, the least‑squares mean differences in HbA1c from baseline for the HRS-7535 30 mg, HRS-7535 60 mg and placebo groups were -16 mmol/mol (95% CI -19, -14) (-1.5% [95% CI -1.7, -1.3]), -20 mmol/mo
- HRS-7535 60 mg · weight_unsp · Abstract RESULTS
(6.5%) were 35.3%, 37.7% and 3.9%, respectively. Body weight loss was -2.4% in the HRS-7535 60 mg group vs -0.7% in the placebo group. Most treatment-emergent
- HRS-7535 60 mg · ae_dc · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
TEAEs leading to treatment discontinuation 1 (2.0) 0 0
- HRS-7535 60 mg · nausea · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
Nausea 1 (2.0) 8 (15.7) 11 (21.2)
- HRS-7535 60 mg · vomiting · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
Vomiting 1 (2.0) 7 (13.7) 10 (19.2)
- HRS-7535 60 mg · sae · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
Serious adverse events 0 4 (7.8) 2 (3.8)
- HRS-7535 60 mg · hba1c · Abstract RESULTS
placebo (n=51). At week 16, the least‑squares mean differences in HbA1c from baseline for the HRS-7535 30 mg, HRS-7535 60 mg and placebo groups were -16 mmol/mol (95% CI -19, -14) (-1.5% [95% CI -1.7, -1.3]), -20 mmol/mo
Registered trials (7)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| RENEW-CKD Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease | CKD | Phase 3 | not yet recruiting | 2026-07 → 2031-05 | 3690 | not yet recruiting | NCT07625774 |
| NCT07528027 Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity | Hypertension | Phase 3 | recruiting | 2026-05 → 2027-12 | 648 | recruiting | NCT07528027 |
| NCT06820099 Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity | HFpEF | Phase 2 | recruiting | 2025-04 → 2026-12 | 225 | recruiting | NCT06820099 |
| NCT06904105 A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity | Obesity | Phase 3 | completed | 2025-04 → 2026-04 | 556 | Completed; results not in the atlas yet | NCT06904105 |
| OUTSTAND-2 A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin | T2D | Phase 3 | completed | 2024-09 → 2026-05 | 810 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT06589765 |
| OUTSTAND-1 A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise | T2D | Phase 3 | completed | 2024-09 → 2025-11 | 284 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT06672172 |
| SOLID-DKD Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes | CKD | Phase 2 | completed | 2024-06 → 2025-07 | 281 | Completed; results not in the atlas yet | NCT06415214 |
Primary sources
- Miao Yu et al. Oral small-molecule GLP-1 RA HRS-7535 as monotherapy in Chinese adults with early type 2 diabetes: the OUTSTAND-1 Phase 3 trial. Abstract LBA 39. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: LBA SO 01 Eat, signal, treat: the rise of incretin therapies]
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd66720.
- Kailera / Hengrui. Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of HRS-7535/KAI-7535 (HARBOR-1, OUTSTAND-2) (GlobeNewswire via BioSpace) [press release]. 2026-07-07. Available from: https://www.biospace.com/press-releases/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-phase-3-clinical-trials-of-oral-small-molecule-glp-1-receptor-agonist-hrs-7535-kai-7535
- Xu M, Song W, Lv F, Fu Y, Yang L, Bin X, et al. Efficacy and safety of HRS-7535, a novel oral small-molecule glucagon-like peptide-1 receptor agonist, in participants with type 2 diabetes mellitus inadequately controlled by metformin and sodium-glucose co-transporter 2 inhibitors: a multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase II trial. Diabetologia. 2026. PMID: 42875600.
How to cite this page
Cite the primary publication for any single result; every value above links to it.